To tell you everything at the editorial office Croblanc, we know all the interest that our community has on the Youtube channel of Bloomberg Television. With each new content, the interest is always bigger, whether it's on our website or even on social networks. And that's why we're telling you about it today, this brand new video should interest you.
Indeed, the Youtube channel Bloomberg Television has decided today to post a new video which is called "FDA to Revisit Opioid Labeling for Chronic Pain". Of course, you can now find it in full playback on our site for your greatest pleasure!
The video is doing a very good start since it was uploaded on the Youtube channel of Bloomberg Television and it could well end up in trend if the scores remain at these levels. However, we should not get too excited and wait a few days to see if this good start is confirmed with a buzz on the duration.
There may be a case where you need to contact the videographer author of this video to give him your criticism, remarks or advice. That's why Youtube has set up an "About" section that will allow you to contact all your favorite youtubers and all the channels you need. In case you can't reach the channel you want, you can still use social networks such as twitter where it's very easy to send a message to bring up an information.
We are almost at the end of the news about the video FDA to Revisit Opioid Labeling for Chronic Pain, all the team Croblanc hopes that you found it interesting to read. We keep our fingers crossed that you will come back to Croblanc very soon to follow the next videos of Bloomberg Television, think of going also to Youtube to find other exclusive contents.
Ladies and gentlemen, we are coming to the end of this article Croblanc, we hope you have enjoyed reading it, at least as much as we have enjoyed writing it!
For your information, you can find below the description of the video FDA to Revisit Opioid Labeling for Chronic Pain published by the Youtube channel Bloomberg Television:
FDA Commissioner Dr. Marty Makary says the agency will revisit the labeling system for OxyContin and similar drugs, saying the original approval for chronic pain was “based on a 14-day study” and tainted by “regulatory capture.” He plans to ensure that a new system is consistent with the science. The action follows an April Bloomberg Businessweek investigation into how the agency’s labeling helped ignite the opioid crisis.
--------
More on Bloomberg Television and Markets
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9
Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more.
Connect with Bloomberg Television on:
X: https://twitter.com/BloombergTV
Facebook: https://www.facebook.com/BloombergTelevision
Instagram: https://www.instagram.com/bloombergtv/
Connect with Bloomberg Business on:
X: https://twitter.com/business
Facebook: https://www.facebook.com/bloombergbusiness
Instagram: https://www.instagram.com/bloombergbusiness/
TikTok: https://www.tiktok.com/@bloombergbusiness?lang=en
Reddit: https://www.reddit.com/r/bloomberg/
LinkedIn: https://www.linkedin.com/company/bloomberg-news/
More from Bloomberg:
Bloomberg Radio: https://twitter.com/BloombergRadio
Bloomberg Surveillance: https://twitter.com/bsurveillance
Bloomberg Politics: https://twitter.com/bpolitics
Bloomberg Originals: https://twitter.com/bbgoriginals
Watch more on YouTube:
Bloomberg Technology: https://www.youtube.com/@BloombergTechnology
Bloomberg Originals: https://www.youtube.com/@business
Bloomberg Quicktake: https://www.youtube.com/@BloombergQuicktake
Bloomberg Espanol: https://www.youtube.com/@bloomberg_espanol
Bloomberg Podcasts: https://www.youtube.com/@BloombergPodcasts